Figure 16

Method for Obtaining Non-Stochastically Generated Polypeptides that can induce a Broad-Spectrum Immune Response.





Figure 17

Possible factors for determining whether a particular polynucleotide encodes an immunogenic polypeptide having a desired property.



The state of the s

Figure 18





Figure 19

Strategy for pooling and deconvolution as used in antigen library screening



Polynucleotide functional group

Expression regulatory sequence

Expressed sequence tag (EST)


Open reading frame (ORF)

Repressor/transactivator

Origin of replication

Gene pathway

Preferred embodiments of site-saturation mutagenesis Figure 20.



II. MUTAGENIC CASSETTES WITHIN SEQUENCE TO BE MUTAGENIZED (

example, a set of mutagenic cassettes is a set of nucleotide cassettes that are not shared by aligned codons within a sequence of defined length. Alternatively, in another preferred but non-limiting differently (i.e. immediately adjacent, evenly spaced, or unevenly spaced) and of any size. In preferred but non-limiting exemplification a set of mutagenic cassettes is a set of contiguous include any polynucleotide cassette of 1-500 bases in length. Site-saturation mutagenesis is sequence to be mutagenized. As shown, cassettes can be spaced along each polynucleotide Mutagenic cassettes that can be mutagenized by non-stochastic site-saturation mutagenesis servicable for mutagenizing a complete set of cassettes contained within a polynucleotide related polynucleotides

III. TYPES OF MUTATIONS THAT CAN BE INTRODUCED INTO MUTAGENIC CASSETTES

The type of mutations to be introduced in a set of mutagenic cassettes can be of the same type or ठ mutagenic cassette (within the nucleic acid sequence to be mutagenized) preferably is usually mutagenized by the use of a corresponding oligo (including by a degenerate oligo). Examples of different types within each round of polynucleotide site-saturation mutagenesis. Each degenerate mutations provided by this invention include:

● Codons for all 20 amino acids (e.g. N,N,N or N,N,G/T or N,N,G/C)

All degenerate codons that do not change the amino acid sequence of the parental template
 (i.e. codons for the same amino acid that is present in the parental template)

Codons (all or selected) for amino acids within the same grouping according to the selecter
amino acid grouping scheme*.

Codons for at least 1 amino acid in each amino acids group*.

*Exemplary amino acid grouping schemes (notes, some groups overlap each other): Acidic (Asp, Glu, Asn, Gln)

· Sulfur-containing (Met, Cys)

· OH-containing (Ser. Tyr. Thr.)

· Basic (Lys, Arg, His) · Aliphatic (Gly, Ala, Val, Leu, Ile) Aromatic (Phe. Trp, Tyr)

· Polar (Ser, Thr, Cys, Asn, Gln, Tyr)

ly, Ala, Val, Leu, Ile, Met, Phe, Trp, Pro) · Non-polar (Gl

Figure 21
Schematic representation of a multimodule genetic vaccine vector (relative sizes of functional units are not drawn to scale)




Figure 22A and 22B Generation of vectors with multiple T cell epitopes.




Figure 23

Generation of optimized genetic vaccines by directed evolution





Figure 24

Recursive application of directed evolution and selection of evolved promoter sequences as an example of flow cytometry-based screening methods.



WO 02/092780

Figure 25.

An apparatus for microinjections of skin and muscle.




Figure 26 Panel A

Non-stochastic polynucleotide reassembly in combination with non-stochastic polynucleotide site-saturation mutagenesis.

Shown below is a non-limiting example of a permutation of the directed evolution methods described herein




Figure 26 (continued) Panel B

Screening of experimentally generated molecules produced by non-stochastic polynucleotide reassembly in combination with non-stochastic polynucleotide site-saturation mutagenesis




Figure 27

Vector for promoter evolution




Figure 28
Iterative evolution of inducible promoters using directed evolution and flow cytometry-based selection.




Figure 29

The present invention provides that a genetic vaccine can be subjected to directed evolution in order to achieve improved effectiveness upon administration by oral, intravenous, intramuscular, intradermal, anal, vaginal, or topical delivery methods.

The figure below shows an example of the directed evolution of a genetic vaccine, comprised of an M13 phage-based vaccine, to achieve optimization for oral delivery.




Figure 30

An alignment of the nucleotide sequences of two human CMV strains and one monkey strain.

		•		•		•
•		1	•			E0.
AF026939 CMV	(1)		agető	merenant	2 20222 xe	50
AF047524 hum UL104	(1)	an surrey and	MGG I Managara	- WALLACE ALT	i-Gentgram	CAGTAAG
AF078102 Rhesus	2 2 2	- GIAGICAAT	T <u>ÇE</u> ĞTATĞGAC	CECCAGGACG	CCGGGGATCAT	CAGGGCC
AFU/6102 Rhesus	(1)	ATEGATATA	-gtggccga	-MGAGGTEG	ICGCIGAACAC	TTTGTGA
						640
		51				100
AF026939 CMV	(38)	CTARAAACAAA	ATCAACCGGGA	ECECAGCITATI	rédélaciona	deen xx.
AF047524 hum UL104	(49)	TCGATTTTCAA	1777cdc			icigina and
AF078102 Rhesus	(47)	CHETTOTACEN	CCU NO MAN INCOME			GCTCCTC
	, ,		GGTÄGATATÇÃ	ENDI-REVIOL	-CHCHAGAGGC	rearcay.
		101				
AF026939 CMV	1071			W_10. Service 7	MA 34	150
	(87)	GAGGGARCA	ŢĠ <u>Ŗ</u> ĠŦĠŖĠĠŢĔ	<u>acgaaga</u> att	CCEGGAGAA A	ATCCT
AF047524 hum UL104	(94)	GTERECEGTGA	ŢĊŖĠĠĊĠĠĊĠĠ	G <u>eog</u> cece	ETTTGAAGCG	TTCCTGG
AF078102 Rhesus	(95)	GCGTGGGTAC	ATÄTCTĞAAĞ Ğ	AGCGAGATGAC	ĞĞÜCĞC-ĞĀĞ	GACGTGA
_					to have the confidences	
· .		151				200
AF026939 CMV	(133)	CECACAGOTGA	A Price of the Part of the Par	A	፫፫፴፴ብ መመ <i>ሟላ አ</i> ሊላ	200 200 200 200 200
AF047524 hum UL104	(142)	GEOSCOS - G			ZERTUT TÜNNG	CAACACA
AF078102 Rhesus	(144)	TARRESTER	いからなっていません。			cecarice
	(244)	TAÇÇÇTÇÇÇGAÇ	twc Gec General	EVG füll GC GIN	MTG1-GGTGT	1.CCYÝCĞ
		201				
AF026939 CMV	/1005	201	There exists as a	4	e	250
	(180)	GIGICACAA	GATOTAGAA	AŢAGAGŢĠŢĠ	TĀĀCC	AĞÄTTGA
AF047524 hum UL104	(191)	CCE-CHCMTTT	<u>}GCGTGGGCGCGCG</u>	CCTTCTCGGG	GÖÜGCAÄÄTÖ	AGCTCCA
AF078102 Rhesus	(193)	TTETETGACTA	PĞTTAÇAĞĞĞT	TTTATCTGCG	ACAATA	CGÁTCAÁ
					pdag Spin Spin	
		251				300
AF026939 CMV	(223)·	ATITTTAX	ACACTGAGTT	2727CT2CZZ	ກາວກິ່ງລ້າວ ກໍ່ໄດ້ຄາການ	ove Sisteman
AF047524 hum UL104	(240)	G-GTATCGGCA	A NOTHICOTION		a artistantificati	
AF078102 Rhesus	(239)	Common No.	so kygy wyggy '' Mer i Aren i	arear sunga	GCGGGCACGA!	CTCGCC
	(455)	GCGTGTTTAGG	lowwith this inter-	ĸ₩₩Ġĸ₩ŢŢĠŢ	<u>egtægtalcyi</u>	MCCG1.1
		201				
AF026939 CMV	12601	301	Total and the same towers.		Strates and company of the company	350
AF047524 hum UL104	(269)	TÄCATÄAÄAÄACAC	GTAGATGGTAA	<u>G</u> AACGAGGCA	ĠĠĊĠĬĠĠĸ <u>Ŗ</u> Ĩ-	-GCTTAC
	(289)	GAAGGAGGT	CAGGTAGGCCI	CGGTACGG-	ĠĠŢĠĊĄĠĊĠŢ-	-ĞÇCCAG
AF078102 Rhesus	(289)	GCGCA<u>B</u>CCC CCTC	TAGCT-GGTTT	ETCÉTCÉTTC	SCTCTGGTATA	GATATT
						,
		351				400
AF026939 CMV	(318)	GGBAACCTGAAG	āgttāāt	CAGORAGEA	ATGCTGAÇCÂ	a contra
AF047524 hum UL104	(337)	CGCCAGGATGTG	TANKS AND	ACCCCACCO	ACGCGCTCTA	iccimin Meciliali
AF078102 Rhesus		ÉCCENGTIAGAA		Cay Con you		CCGIGI Saya
•	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	a legiska inte	Week Carrest	EBHCGWR LWIN	it.i.têchreci	W ACKCO
		401	,			
AF026939 CMV			A			450
AF047524 hum UL104	(364)	AMICAGAAGT	CTAGTCACT	KGGGGAAACQ	-ĂCĠĠĊŢĠĠ ౼ Ġ	TÇTACT
	(384)	aaptegagtaga	CGATEGCCTET	ICEECCCEIT	ATGEGTGA	CCÄGAC
AF078102 Rhesus	(387)	AATTGGAAGC	ACTGĞĞAAŢĀŢ	TEGEGGTGCAC	TTĞĞĞTĞATG	GCAGTG
			~~~ <b>**</b>	Policial Company		
		451				500
AF026939 CMV		ATCA ČTTEGECA	Ĝlendine:	ROKING STATES		000 
AF047524 hum UL104		SCGGCAGGCGAA			TTTATGT	HGWI.WY
AF078102 Rhesus				AV TACTE CLI	TTCCCACAGC	ręce-t
	(400) 4	TOGCAAAAA	I.CCWRAY GACA	<i></i> ccittlelettet	<b>ÄGÄGĞLGGĞY</b> I	AGCTAT
		-04				
35025020 mm		501	the the face to the same	•		550
AF026939 CMV	(451)	ĠtĠàāaċaaĕē	CTGCAAGAAATT	ette <b>xaa</b> tcea	T <u>a</u> cagtattgi	<b>ÇTATT</b>
AF047524 hum UL104	(478)	AGGAAGEGTTE	Jagogactego'i	GCGGGGCÄCG	AACTGC-GAGE	SACADA
AF078102 Rhesus	(485)	gattigtgtäge	TGTATGACTCC	GACAGICATICA	CACHON_mmor	್ಷ ಪ್ರಸ್ತಿತ್ರ
		क्ता है। कि	AND OF HEAD SHOW	and the second	<b>、 はがず~ 4. ずか</b> に	فأنفعه سوفيك

### Figure 30 continued

		551 600
AF026939 CMV	(501)	ÇÎĞAAÇÎÎĞÂĞÎGTGÂĞGAĞĞĞGÎĞGAÇÂĞAÂĞTĞAAGÎGTĞĞÂAĞAAAT
AF047524 hum UL104	(527)	CTG-TTGGCGAGCAGG-CGGTTGTCGTGCAGCGCC-AACGGACG-GAA
AF078102 Rhesus	(534)	GEAGCTCAGTCAGAGEBACTCGCGCGCAGGTT-TACTGACATGTG
	,,,,,,	650
. AF026939 CMV	(551)	GAAAGGCCAAAAGCCCAAAAGCCCAAAAGCCCAAAAGCCCAA
AF047524 hum UL104	(571)	and some the property of the p
AF078102 Rhesus	(579)	AATEGETATATEGCATĈEGCAAATGCCTTCTCCACCACCGAGCCTTC
		651 700
AF026939 CMV	(597)	ACAACECEEATTCTCC-TCTEEACEGETAETTEECATETACETTCTEEA
AF047524 hum UL104	(615)	
AF078102 Rhesus	(627)	ĠŢŢŢŢĠĸĸĠŢĊĠĸĠĸĸĸŢĠŢŢĠŢĠŢĠŢĠĸŢĠĠĸŢĠĠŢĠĠŢ
	·	
		701 750
AF026939 CMV	(646)	T-AATGACGCAGAGAACAGTTGECTACTGATGETTTGAAGCAG
AF047524 hum UL104	(657)	CTICGEGGGGCGAEGCGTAGCGGGGGA-GCAGGICGCGCAC
AF078102 Rhesus	(677)	Ġ-ŢŊĠĔŢĸĸĠĸĊĊĠĊĸĠĸĸĠĸĠŢŢſĠĊĸŢĠĠĊĠŢŢĸĸĠŢĸĸĠŢĸĸĠŢĸĸ
		751
AF026939 CMV	16001	751 800 800 800 800 800 800 800 800 800 80
AF047524 hum UL104	(689) (706)	GEGATTGAGETGAGTECTGATAACGAATACGTGAAGGTTGTCTTTGGG
AF078102 Rhesus	(705)	GGGÉTTCTCGCÁGGTGTGGTTGÁGGGTGCGGÁGGTCGTGGÁATCTCGTCTÁ ACCCCTGGGGGATCGGAGGCCGÁTGCCTTGCTGGGTACTGTGGA
111 0 / 01 01 111 111 111	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	いる際との表表の話したののいのでとの意思も持つのようが、または、これには、これには、
•		801 850
AF026939 CMV	(736)	CCTGAAACTCCAGAAGATGAATAAAGAAGCTGAAGGAGAGAGAGAGTTTCT
AF047524 hum UL104	(756)	GETEGATOTECTCTCTCTCAGGGACTTCATGACCTGCTTCT
AF078102 Rhesus	(775)	GAAGETAEGTŒAAÏETATCCCTTTGETAAAAÏEACAĞCTĞATAAC
17005050 mm	/50.41	851 930 September 2011 September 201
AF026939 CMV	178/13	- バハマックスペースのかかからしょうと イガスのへんがめんとうしょうしょ クリガスがんぶんとんとん カード
	(784)	ŢĠĀĠĀĀĠĊĠŢŢĠĠĂĀĀĀĠŢĊŢĊĊŢŢĠĊĊĀĀĀĊAĠĂŢĠŢĊĊŢĊĊĠĊAĠŢĠ
AF047524 hum UL104	(801)	UANACAGEREGEENTG-TCCCGCEECGCGCGCCCGCCCGCCCGCCCGCCCGCCCCCCC
	-	177 PAGE 10 MILLS TOUR TOUR TOUR TOUR TOUR TOUR TOUR TOUR
AF047524 hum UL104	(801)	TAMCAGGAGGGGATG-TCCCCCCCCCCCCCCCCCCCCCCCCCC
AF047524 hum UL104	(801) (821)	ŢŖŖŖĊŖĠŖĸĠĠĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF047524 hum UL104 AF078102 Rhesus	(801)	TAĂĂCĂGŢĞGĞĞĂTG-TCCCGĞĞCĞGGĞGCĞĞCCĞĞCĞGCĞG-GGTĞ-Ġ TTTĀĞTĂAŢĞŢĞATĂĂĂ-ĞTAŬATŪAAT-ÇĂĂCĞCĂŢĞŬĞŢŢĞ-C 901 GAĞĞCAAĀTŢŢTAÇAĞÃAĞAAÃAGĞTGACCŢÃGAÇAÃÃGÇŢÃŢŢĞĀĀĊŢĞ
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV	(801) (821) (834)	TAMCAGGEGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104	(801) (821) (834) (847)	TAĂĂCĂGŢĞGĞĞĂTG-TCCCGĞĞCĞGGĞGCĞĞCCĞĞCĞGCĞG-GGTĞ-Ġ TTTĀĞTĂAŢĞŢĞATĂĂĂ-ĞTAŬATŪAAT-ÇĂĂCĞCĂŢĞŬĞŢŢĞ-C 901 GAĞĞCAAĀTŢŢTAÇAĞÃAĞAAÃAGĞTGACCŢÃGAÇAÃÃGÇŢÃŢŢĞĀĀĊŢĞ
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863)	TAĂSCĂGGIĞGĞĞĂTG-TCĞCGĞĞCĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞ
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF026939 CMV	(801) (821) (834) (847) (863)	TANCAGGAGGEGATG-TCCCGCGGCGCGCGCGCGCGCGCGGCGGCGGCGGCGGGGGG
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104	(801) (821) (834) (847) (863) (884) (896)	<ul> <li>ÜAĂĂCĂGGĨĬĞGĞĞĞTG-TCĞCGĞĞCĞGĞĞGĞĞCĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞ</li></ul>
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF026939 CMV	(801) (821) (834) (847) (863)	TANCAGGAGGEGATG-TCCCGCGGCGCGCGCGCGCGCGCGGCGGCGGCGGCGGGGGG
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104	(801) (821) (834) (847) (863) (884) (896)	TAM CAGGA GEGERATG TO COCCEGE GEGE COCGEGE COCGEGE COTT OF THE TAM CAR CAR COCATE TO COMPANY TO THE TAM TO THE
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (884) (896) (912)	TANCAGETEGESTETTECCESTEGEGEGEGEGEGEGEGEGEGEGEGEGEGEGEGEGEGE
AF026939 CMV AF047524 hum UL104 AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912)	TANCAGEREGESATG-TCCCCGECGCGCCCCGCCCGCCCGCCGCCGCCGCCGCCGCC
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF047524 hum UL104 AF078102 Rhesus AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942)	TAÑCĂGŒŢĠĠĠĂTG-TCĠĊĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠĠ
AF026939 CMV AF047524 hum UL104 AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942)	TANCAGEREGESATG-TCCCCGECGCGCCCCGCCCGCCCGCCGCCGCCGCCGCCGCC
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF047524 hum UL104 AF078102 Rhesus AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942)	TAĂNCĂGGINGGOSĂTG-TCCCGCTCCGCCCGCCCGCCCGCCGCCGCCGCCGCCGCCG
AF047524 hum UL104 AF078102 Rhesus AF026939 CMV AF047524 hum UL104 AF078102 Rhesus AF047524 hum UL104 AF078102 Rhesus AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942) (961)	TATAGO GO G
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (884) (896) (912) (934) (942) (961)	TANCAGGE GGGGATGATATATATAT CANCEGATET
AF026939 CMV AF047524 hum UL104 AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (884) (896) (912) (934) (942) (961) (984) (986)	TAMCAGGAGGGGATGT TCCCGGGCGGGGGGGGGGGGGGGGGG
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (884) (896) (912) (934) (942) (961) (984) (986) (1004)	TAMCAGET GESTATE TOCOGET GEGE GEGE GEGE GEGE GEGE GEGE GEGE
AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus  AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (884) (896) (912) (912) (934) (942) (961) (984) (986) (1004)	TAMICAGO GOSTO TCCCOSCOGO COCOGO COCOGO CONTROL CONTRO
AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (884) (896) (912) (934) (942) (961) (984) (986) (1004)	TAMECÁGGA GEGESTA TO TO TO TAMENTA AT TAMES A TAMES A TO TAMES A TOTAL AT TAMES A TAME
AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942) (961) (984) (986) (1004) (1032) (1036)	TAMICÁGGA GEGENTA TO COCAGE CEGE CEGE CEGE CEGE CEGE CEGE CEGE
AF047524 hum UL104 AF078102 Rhesus  AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(801) (821) (834) (847) (863) (863) (896) (912) (934) (942) (961) (984) (986) (1004) (1032) (1036)	TAMICÁGGA GEGENTA TO TO TO TATO CONTROL OF THE TAMICA TO TATO CONTROL OF THE TAMICA THAT THAT THAT THAT THAT THAT THAT TH

### Figure 30 continued

•		•
AF026939 CM AF047524 hum UL104 AF078102 Rhesus	(1084)	C-PGG-TCCATG-ATGCCACCAGCTTGTTGCAGCTCGTGGCGGC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1131)	TGGEEGEECCAETTEAEAEGAAAEGTATTCAEGAAETGGCAGATC
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1178)	1300 CAŢCAĞCĞ-ĞTAĞTĞCAAĞĞTŢŐĞĞAAATAŢĀĀŢĠĞGAAGTCŢĞAĄĞĄ TŢŢŢĠĞŢĠĠĠĠĞAĞĄGCĞĞĞŢĞĞTAĞĞÇAĞ-AÄŢĞTĞ-ĞŢĞCAĞG -ŢĠŢĠĠŢĠ-ĞĞTACĞACTGGCŢĞAC-ĞÜĞĞAĞŢŖĂŢĊĞĞĞÇŢĞAŢĞATAÄ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1222) (1226) (1222)	1350 CĂCTGŒŢĠŢĠĔĀĬĠĀŢĠŒŢŢĬĬĠĬĠĠŢĠŢŢĬŢĠŢĠŢĠŢĠŢĠŢĠĬŢĬĬĠĊĀĀŇĀ TĠŢĠĊĠĀCĠĠĠĠŢĠŢĠŢĠĀĬĠĀĊĬĠĊĬŢĠŢĠĠĠĊŢĠĬŢĬĬŎĠĊŎŊĠĆ ĀĬŢĀĠŒĨĀĠĊĬĠŢŢĠŢŢĠŢĠĠĠĨĊĠŢĀŒŢĠĀŢŢŢĠĬŢĠĊĊŢŊĠ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1266) (1274) (1267)	1400 AAÏCAACĪGAĞĀĀĞ-ĞAĀGĀGATCAĀAĞACĒAACĒACAĞAĀŢGŢAŢCĞGĀ GĞŢTCGGŢCĞĒCĀC-ĞTĀCĀĀĞCGGĀŢĞŢĞĞTŢĞĒĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞĞ CĞGAGTAŢTĞÇĀĀĞAĞĀĞTCĀĞAATTGĞŢĞÖŢŢŢŒĞĞŢĞGĀĞÇAĞŢĞTÇĀ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1315) (1323) (1317)	1450. AAÄTCTGGTTGCACAÄÄATGGÄGGÄÄTTATTGGTÄTCTTCÄAGGÄ GCÄGCCGCTCGGÄGCGCÄEETTCTTGAAGACGCGTÄCCTCGGGC ÇGGTTGTAGÄÄGGGECCCEÄÄÄGCGGTGCGTGGCAÄGAAÄ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1361) (1367) (1356)	1500 TÍAĂÑTCAŤĂĂĠĠĄĠĸĸĸĠĠĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1413)	1550 ĢAĀĞGAĀĞTĞĞGCCĞĞĞTĞĞ—TĀAĞGGAŢĞĞCĞĞTTĞAĞĞCAÑ—AĞGĞ ĞCĀĞCGCĞAĞĞTTAĞĞĞTĞĞAGĞAĞĞĞTĞTĞĞĞĞĞĞĞĞĞĞĞĞĞ
AF026939 CMV. AF047524 hum UL104 AF078102 Rhesus	(1457) (1462)	1551 AĞĪATTŸŢĠĊŢĠĊĀĠĊAŢĠŢĠĀĠĠŢŢĠĂĠĠĬŢĠĠŢ-ĂĠŢĠĀĠĠĄĄĄŢĠĠ ĠĠŢĠĠŢij-ĊĠĊŢĠĊĀĊ-ĠĠĠĊĠĊĠĊĠŖŖĸĊĸĸĬŢŢĠĕĠĊĊĊĊŢĊĠĠĊ ĠĸŢĠĸĠĨĸĊĸŎĸŎĸŎĸĬĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸĸ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1506) (1508)	1650 ĢĒĒAGGĢĒ-GĒĀĒTÇĀĠCŢĒCAĞŢĒĒÇĀĠĀĠĀĠĀĢCŢĊĢTĀĀÇTĊ ĢĒĒĪĒ-ĒĒ-ŢĒĠĒĊŢŢĠĠŢĒŢCAĊĢŢĒĒAĠĊĀĠĊĢĠŢĀĊĈĀĠŢĊĊ ĊĠĔŢĠĀĢĔĀŢĒĀĠĊŢĠŢŖĠŢĊĀŢŢŖĒŢŢŖŢŎĀŢĢĀŢĀŢ-ĢĀĀĀĢĀĀĀCGĠĊ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1552) (1553)	1700 ÁĞAĞCAAĞTĞAAĞTGAĞĞGĞĞĞĞĞĞĞĞAAAĞCAĞAĞA—AİĞĞGAĞÇÇT ÁCCĞÎTÂĞ—ĞÇAĞCAAĞÇÇĞĞÇĞĞAĞAÇAĞAÇAĞĞĞÇĞĞĞ ÁĞTĞÎTĞ—————AĞTÇĞTTAĞĞĞTĞATĞĞĞĞĞĞĞĞĞĞĞĞ
AF026939 CMV AF047524 hum UL104 AF078102 Rhesus	(1600) (1602) A	1750 GAGTGGTGGTGGTĞAÇĞGĞTAGĞAĞGATAGGAAĞAĞAĞAĞAĞGÇĞCCAA CTGATATAA-ATGTÇĞĞ——ĞAĞĞĞĞĞĞĞĞĞĞĞĞĞATATATĞĞÇĞATAA CTÇAĞATATACÇĞĞ

Figure 31

An alignment of IL-4 nucleotide sequences from 3 species (human, primate, and canine).


AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	1 (1) TGCATCGTTAGGGTCTCCTAGTATAGTGTTTTGTCACTGC (1) TGCATCGTTAGGGTTTGTCCTGATATAGTTATTTGTCACTGC (1)	
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	51 (51) AAATAGAGATCTATTAATGGGTGTCAGGTGCCAACTGCTAGGGCTGTGGG (50) AAATCGACACGTATTAATGGGTGTCAGGTGCCCAACTGCTTCCCCCCTCTGT (1)ATGGGTGTCAGCTCCCCAACTGCTTCCCCCCTCTGT	i i
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	101 (101) PERGETTAGRAGEACTCAÇEAGEACETTRETECACEGACACAACTTCAAT (100) PERCERCETAGEATETCECEGEACACATETCAAT (35) TERRETECTAGEATETCECEGEAACTTRECEGEACACAACTEGECAT	
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	200 (151) ATTAGTATATACACATOATICAVAATGTECAACATCCTCACAGAGCGAGAAA (150) ATCACCTTACACACACATCATCATCATACACTCTCACAGAGCTCACAGAGCAGCAGCAGAGCAGCTCACAGAGCAGCAGAGCAGCAGAGCAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGAGCAGAGCAGAGCAGAGCAGAGCAGAGCAGAGAGCAGAGAGCAGAGCAGAGAGCAGAGAGCAGAGAGAGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG	Ž
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	250 (201) CGACAT-GTEGATGAGCTGAGTGAGGAGGAGGTGATCAGTGGTCCAAAG (199) AGACATTGAGGAGTTGACGGTAAGAGATGATTTGGTGGCTCCAAG (134) AGACATTGAGGAAGTTGATGATAACGGAGATCCTTGCTGCCTCCAAG	75. 75.
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	251 (250) ĂĂĠĂĠĂĬĠĊĠĂŦĂĬĠĠĂĬĂŢĊĬĬĠŨĬĠĠĂĠĂĠĊĬĠĠŢĀĊĬĠŢĀĊŢĠĊĠĠĊĀ (249) ĂĂĠĂĠĂĬĠŢĠĬĠŎĬĀĠĠĀĬĀĠĠĬŢĠĬĠĠĂĠĠĠĊŢĠĊĠŎĊĬĠŢĠĊĬĊĊĠĠĊĀ (184) ĂĂĠĂĠĂĬŎŢĠĀĠĀĀĠĠĀĬĀĠĠŖĬĬĠŢĠĊĬĠĊĠĠĊĬ	į
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	350 (300) GATCTATACACACAAGAAGAACTEGCTCCTGGGTGCGACTGCAC (299) GTTCTACAGCACCATGAGAAGGACACTCGCTGGGTGCGAGTGCAC (234) GTTCTACAGCACCATGAGAAGGACACTCGCTGCGTGCGAGTGCAC	_
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	400 (319)ŤĒČĀĀĒĀĞĂŤATĆŪCĀĞĀĞĞAČŤČTĀČ (349) ĀĞĒĀĞŤŤĒĞĀCĀĞĞĒĀĀĀĞĞĀĞĞŤĞĀŤĊĊĞĀŤŤĊŨŤĠĀĀĀĊĠĠĊŤĊĠĀĊ (284) ĀĞCĀĞŤŢŌĊĀĊĀĞĠĊĀĒĀĀĞĊĀĠĊĪĠĀŤĊĊĠĀŤŤĊĞŢĠĀĀĀĊĠĠĊŤĊĠĀĊ	
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	401 (346) AĞĞARĞÜĞAĞCAĞĞARĞĞARĞĞAAĞAAĞAÇÜRĞİTÇİTATĞAATĞAÂAT (399) AĞĞARĞÜTÖTGGGGÇÜRĞĞĞĞÜRĞAATİÇĞTĞİÇÇÜĞİĞAAĞGAAĞÜ (334) AĞĞARÇÜTÇTEĞGGGÇÜNÜĞAACTÖÇTĞTĞAAĞGAAĞC	
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	451 (393) CĂĂGAĂĞĂĞTĂĞACTĞAĂĂĞACTTCTTCCAXĂĞĞÇŢĂĂĂAGTGATÇATĞC (449) CĂĂCCĂĞĂĞTĂCCTTGĞAXAQTTCTTCGAXAĞĞÇTĂĂĞĂĞĞATCATĞA (384) CĂGCCĂĞACTĂCĞTTĞĞAĂĞACTTÇĞĞAXAĞĞCTAXĀĞÂCĞATCATĞA	? <u>}</u>
AF187322 Canis IL-4 NM_000589 Homo sapien IL-4 U19838 Cercocebus IL-4	550 (443) AGAĀGĀĀĀTĀCTĀCĀGĢCATĪGAĀĢCTGĀĀTĀTĀTĀĀTTĀTĢĀĢTTTT (499) GĀGĀGĀĀĀTĀTĪCĀĀĀGTGTĪCGĀĢCTGĀĀTĀTĪTĀĀTTĀTGĀĢTTTT (434) GĀGĀGĀĀĀTĀTTCĀĀĀGTGTTCGĀĢCTGĀĀ	•

### Figue 31 continued

AF187322 Canis IL- NM_000589 Homo sapien IL- U19838 Cercocebus IL-	4 (549)	551 IACATAGOTTATATATATATATATATATATATATATATATATA
AF187322 Canis IL- NM_000589 Homo sapien IL- U19838 Cercocebus IL-	4 (598)	601 EXTATATATATATATATAAAAAAAAAAAAAAAAAAAAA

Figure 32


Evolution of polypeptides by synthesizing (in vivo or in vitro) corresponding deduced polynucleotides and subjecting the deduced polynucleotides to directed evolution and expression screening subsequently expressed polypeptides.



### Figure 33

### Directed evolution of polynucleotides (e.g. promoter sequences)

This figure shows an example of the application of non-stochastic site-saturation mutagenesis in combination with non-stochastic reassembly (e.g. oligo-directed CpG deletion(s) and/or addition(s))






Figure 34

An example of a CTIS obtained from HbsAg polypeptide (PreS2 plus S regions).




Figure 35

An example of a CTIS having heterologous epitopes attached to the cytoplasmic portion.






Figure 36
Method for preparing immunogenic agonist sequences (IAS).



Poly-epitope region containing potential agonist sequences



Further optimized poly-epitope region containing potential agonist sequences




Figure 37
Improving Immunostimulatory Sequences (ISS) Using Directed Evolution.




Figure 38

Screening to identify IL-12 genes that encode recombinant IL-12 having an increased ability to induce T Cell proliferation.




Figure 39

anergy by genetic vaccine vectors encoding different CD80 and/or CD86 variants. Model of induction of T cell activation or





Figure 40

Screening to identify CD80/CD86 chimeric genes having an improved capacity to to induce T Cell activation or anergy.



### Figure 41

Figure 41. An alignment of two CMV-derived nucleotide sequences from human and primate species.




Figure 41 continued

AF078102 Rhesus M67443 Towne	(682) (620)	750 PAAGACCECAGAAGAGTTTCATGGCGTTAGCCTAGTGAAAACCC-CT HECAGETGATAGGTGACCEGTAGGETGTACCEGAGTGGTTGET
AF078102 Rhesus M67443 Towne	(731) (668)	751 EGECEATEGAEGEGATCCETTE CONCING GUACTETGEAGAAG GCEAGGAEGT-GCEETCCGGGAAEGETTETALECACETTEGECTC
AF078102 Rhesus M67443 Towne	(†79) (717)	801 CTTECTCAPETGTATECCTATAATCAGAGTGATTATTAGTAA TGLECTGGAAGGAGGTGACGAGGACCCCGCAACGCAGCACCAGCAGCAGCA
AF078102 Rhesus M67443 Towne	(829) (767)	900 TETEETAMAGTATATTAAHCAAKECATGEETTGEEGABGAA GECECCACGAGCGCAHCGCTTACGGTGTGTGTGTCCAAAATATGAHA
AF078102 Rhesus M67443 Towne	(871) (817)	901 EGTAGTTEGTGTT - CIGCO-EGITACECIAATHTEGAATEATGGGG ATEAANECGGGCAAGATETCGGAGATCATELEGGATGTGGCTTTTACCTC
AF078102 Rhesus M67443 Towne	(917) (867)	951 AGCTETEGRAJIAATTCTETTEGACGAETGEGGCETETGTTATETEG-TEA AGACGAGCATTTIGGECTECT-ETETCECAAGAGCAECCEGEGCTEA
AF078102 Rhesus M67443 Towne	(966) (914)	1050 EANTCGACGAAAGEGACGTCTTTEGTCTAGECEATAAGATEGAAATGT GCATCTCAGGTAAGCTATTGATGAAGGGGCAGGAGATGTTTCGTGGAGG
AF078102 Rhesus M67443 Towne	(1014) (962)	1051 IGTTCAGATGCGGCTITGTTAAGCTGGCTGGCATTTAAGCGCATTTGAGCGC IGCAAGCGATACGCGAGA-GCETGGAACTGGGTCAGIAC
AF078102 Rhesus M67443 Towne	(1064) (1000)	1150 GEANTGEGTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
AF078102 Rhesus M67443 Towne	(1109) (1048)	1200 GAGGGTGACGGTAAGCAAGATGTGTGTTGTGTGTGTGTGT
AF078102 Rhesus M67443 Towne	(1159) (1096)	1201 TAREGCCGAGEAGCTCTTTTGTGETT-AGGAGTGGCTCAGGCGGAGTTAT ATCCAGGCGAGCTTGAGTACCGACAGACTTGGGGGAGTGAGTACCGACAGACTTGGGGGAGAGTACCGACAGACTTGAGTACCGACAGACTTGGGGGAGAGTACGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACAGACTTGAGTACCGACAGACTTGAGTACCGACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGTACAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAGACTTGAACTTGAACTTGAACAACAACAACAACAACAACAACAACAACAACAACAAC
AF078102 Rhesus M67443 Towne	(1208) (1142)	1251 CECECTEATGATĂAAATACETĂECĂGTEGETETTGGEGACGĂAETGAETT AGGETGECGCCCEGGGCGAEGĂEGECGECEGACCCC
AF078102 Rhesus M67443 Towne	(1258) (1192)	1301 ENTECCTECEGRATATTGCAAEACAATCACAATTGGTCGTECTECAACACCCCCCCCCC
AF078102 Rhesus M67443 Towne	(1308) (1241)	1351 SEAGTETERCEGTTCTAGAAEGEE - ECTAAGGGETECETGETE - BAR GEGECECETEGEGGECEGTEEACTTECECEGECCEGAAACECA

# Figure 41 continued

AF078102 Rhesus M67443 Towne	-	
AF078102 Rhesus M67443 Towne	•	
AF078102 Rhesus M67443 Towne		1501 .  EACTRCAGAGRAGAGGAGGAGGATGATGATARCGAGTGAGAAGAAGGCCC GAGGATTGCGACAACGAGATCCCCAGTCCGGCCGTGTTCAGGTG
AF078102 Rhesus M67443 Towne		1551 TEAGGATCAGECTETTETEATTGATATEATTGATAACAAACGGGAGTGATE GECGECCTGECAGCCGGGATCCEGGGCAGCCAGCAGCCGGTGCCATGGATG
AF078102 Rhesus M67443 Towne	(1554) (1475)	1650 ATTATATGATGATGAGAGTCAH-ETCTEECCT-EAEATAGCGA CTAGGGTECAGGGCCAGGAGTCATGAGGAGTCTTTTTTTTTT
AF078102 Rhesus M67443 Towne	(1600) (1525)	1700 TGATGCAECAECCECAGACATTATGECECATAATCCATAAGGAATTECECAAACGACATCTACEGCATCTTCGCCGAATTTGGCAAGGCCTATTGGCAGCC
AF078102 Rhesus M67443 Towne	(1648) [*] (1571)	1701 
AF078102 Rhesus M67443 Towne	(1689)	1800 GGGGGGGAEGAGGA-GGTAAACATATGAAAAAAAGGGGCATTGTTAGGT GCGATGGATCGGCTGGACGGCCAAAAAAAAAGGGGTTGAGCCACCGGGC
AF078102 Rhesus M67443 Towne	(1735)	1801 GGAAAGGGTAAGCAETTATCACCETTEAATGETAATATTTEAET GCGCACGCTAAGAAAAAGCEACGTCCAGACAGGCA
AF078102 Rhesus M67443 Towne	(1779) (	1900 GCTTGATTAAACAATGCATTTGTATTAATTATCTAATTCCCGTGTA ACTTTTGGCCGCGACACCTGTCGCGCGCTATATTTGCCACAGTTG
AF078102 Rhesus M67443 Towne	(1827)	1950 CETGTEATERTECATGEAGTGGTGEGIANGATAN TATERAGAGA CEGAAGCCETCCEGAECTCCCACGAGGACCEGET-CACCERTIGCG
AF078102 Rhesus M67443 Towne	(1877) -	2000 PAGGRATGAGTTGTGAAAGGRGTGAARATCATGCAATRGTCGCAAGGA CECHGAGCCCCCCECATCCCGCCTTCGCGATGLCECAEGGAT
AF078102 Rhesus M67443 Towne	(1926) G	2050 GTCEGGGTTCGTTCTTTTTTTTTTTTTTTTTTTTTTTTT
AF078102 Rhesus M67443 Towne	(1975) T	2077 GETTEARTETETETETETETETETETETETETETETETETE